PCSK9 and prostate carcinoma: As drug target MR analyses, particularly when using only a single cis-acting variant as an instrument, are susceptible to false-positive findings due to LD structure with nearby genes [55,56], we conducted genetic colocalization at this locus to evaluate evidence of a shared causal variant between PCSK9 expression in liver tissue and prostate cancer.